Zerbaxa FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 7, 2020.
FDA Approved: Yes (First approved December 19, 2014)
Brand name: Zerbaxa
Generic name: ceftolozane and tazobactam
Dosage form: Injection
Company: Merck
Treatment for: Intraabdominal Infection, Urinary Tract Infection, Pneumonia
Zerbaxa (ceftolozane and tazobactam) is a cephalosporin and beta-lactamase inhibitor combination for the treatment of:
- complicated intra-abdominal Infections (cIAI), used in combination with metronidazole
- complicated urinary tract infections (cUTI), including pyelonephritis
- hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
Development timeline for Zerbaxa
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
